Insights on Molecular Heterogeneity in Endometriosis Treatment – HER Heard
HER Heard shared a post by Femtech Insider on LinkedIn:
“Important breakthrough in our understanding of Endometriosis: ‘Endometriosis is currently classified based on symptoms and anatomical or surgical features, but these approaches don’t capture the biological programs active inside the tissue. Our work shows that what looks like unpredictable variability between patients actually reflects recurring cellular states that shape how the disease behaves and responds to treatment. This creates an opportunity to move toward more biologically informed patient stratification in research and clinical trials.'”
Quoting Femtech Insider’s post, adding:
“France-based biotech endogene.bio has published research suggesting that endometriosis is molecularly heterogeneous across patients, lesion sites, and cell types – a finding that could help explain why patients often experience different outcomes with the same therapy.
The preprint, titled ‘Beyond one-size-fits-all: single-cell transcriptomic signatures predict drug efficacy and reveal responder subgroups in endometriosis,’ combines single-cell RNA sequencing with a computational drug-response framework to identify distinct cellular response patterns that may predict which therapies are most likely to work for specific patient groups.
‘Endometriosis is currently classified based on symptoms and anatomical or surgical features, but these approaches don’t capture the biological programs active inside the tissue. Our work shows that what looks like unpredictable variability between patients actually reflects recurring cellular states that shape how the disease behaves and responds to treatment. This creates an opportunity to move toward more biologically informed patient stratification in research and clinical trials.’ Cristina Fernández Molina, Co-founder and Head of Science at endogene.bio
Full story.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 10, 2026, 06:50Owen Xian Wen Tan: New Insights on β2-Glycoprotein I in Thrombosis Regulation
-
Jan 10, 2026, 06:35John Cush: Assess Reproductive Health in SLE Clinic Visits
-
Jan 10, 2026, 06:25Explore Key Topics in Rheumatology at RheumReview 2026 – Canadian Rheumatology Association
-
Jan 10, 2026, 06:07Exploring Gut Health’s Role in Endometriosis Management – Womb WatchAI
-
Jan 10, 2026, 05:33Yasmin Magdi: Critical Concerns In POSTAL Study on Thyroid and IVF
-
Jan 10, 2026, 03:00Naila Jabeen: Understanding Genetic Factors in IVF Success
-
Jan 9, 2026, 11:20Lucile Ferreux: What History Teaches Us About the Place of Human Health
-
Jan 9, 2026, 11:02January Insights Reflecting on 2025’s Top Fertility Research – RBMO
-
Jan 8, 2026, 19:00Michaela Hofbauer: 2025 Marked a Turning Point for Women’s Health